Publication: 4550

Publication: 4550

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201.

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Leuk Lymphoma vol 66 (10) 1903-12

Year:: 2025
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 14

Parents:: 4133
Children:: None

Program:: OGC
Primary Committee:: Lymphoma
Sec. Committees:: Transplant

Pharmas:
Grants:: U10CA180821, U10CA180882, U24CA196171; UG1CA189824, UG1CA189961, UG1CA233198, UG1CA233253, UG1CA233290, UG1CA233320, UG1CA233339, U10CA180820, UG1CA233234 (ECOG-ACRIN); U10CA180868 (NRG); U10CA180888 (SWOG);

Corr. Author:
Authors:: Charalambos Andreadis Olivia Bobek Eric D Hsi Timothy S Fenske Patrick J Stiff Brian T Hill Susan M Geyer Mitchell Horwitz Farhad Khimani Richard F Little Shira N Dinner Jonathan W Friedberg Brad S Kahl Miguel-Angel Perales Steven M Devine John P Leonard Nancy L Bartlett

Networks:: CA824, FL065, IL017, LAPS-IL036, LAPS-MN026, LAPS-MO011, LAPS-NC010, LAPS-NY016, LAPS-OH007, LAPS-WI013, NY018, OH027, PA121

Study: Alliance-A051301
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: